Breaking News Instant updates and real-time market news.

VCYT

Veracyte

$7.73

-0.04 (-0.51%)

13:58
02/17/17
02/17
13:58
02/17/17
13:58

Veracyte strength attributed to revised BCBS of Tenn. policy draft

The move higher in shares of Veracyte is being attributed to a draft of a revised policy from BlueCross BlueShield of Tennessee. The draft, which states "Do Not Implement" at the top, shows changes that read, "Testing of molecular markers in fine-needle aspirates of the thyroid is considered medically necessary if appropriateness criteria are met." Veracyte makes Afirma Thyroid. Reference Link

  • 01

    Mar

VCYT Veracyte
$7.73

-0.04 (-0.51%)

11/29/16
JANY
11/29/16
UPGRADE
JANY
Buy
Veracyte upgraded to Buy from Neutral at Janney Capital
11/29/16
JANY
11/29/16
UPGRADE
JANY
Buy
Veracyte upgraded at Janney Capital
As noted earlier, Janney Capital upgraded Veracyte to Buy from Neutral. Analyst Paul Knight says that the company's "disciplined test development, commercialization, and reimbursement processes" insulate it from a number of problems plaguing the pharma sector. He thinks that recent regulatory changes have "dramatically reduced" the company's pricing risk. Target to $16 from $8.
11/29/16
11/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Overweight from Equal Weight at Barclays with analyst Geoff Meacham saying he sees a greater likelihood that Pfizer will be able to access its cash overseas under the new administration, which could be used to acquire growth assets and return capital to shareholders. 2. Comerica (CMA) upgraded to Outperform from Market Perform at Keefe Bruyette. 3. Tractor Supply (TSCO) upgraded to Buy from Neutral at Northcoast with analyst Chuck Cerankosky saying he expects the company to benefit from colder weather and the improving US economy and said product assortments and promotions have also been adjusted to the new economics of the energy patch and its impact on this company's customers. 4. Del Frisco's (DFRG) upgraded to Outperform from Neutral at Credit Suisse with analyst Jason West saying it is a key beneficiary of improved high-end consumer and corporate spending. 5. Veracyte upgraded to Buy from Neutral at Janney Capital with analyst Paul Knight saying the company's "disciplined test development, commercialization, and reimbursement processes" insulate it from a number of problems plaguing the pharma sector. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/08/17
CANT
02/08/17
NO CHANGE
Target $13
CANT
Overweight
Veracyte pact with Quest should improve Afirma reimbursement, says Cantor
Cantor Fitzgerald analyst Bryan Brokmeier believes Veracyte's (VCYT) agreement with Quest Diagnostics (DGX) for its Afirma Gene Expression Classifier expands access which, in addition to accelerating growth, should improve reimbursement rate and margins. Other diagnostic partners have said that Quest has become more of a driver of sales of proprietary tests, particularly for higher value tests, which leaves Brokmeier encouraged that the partnership will pay off for Veracyte, he tells investors. The analyst reiterates an Overweight rating and $13 price target on Veracyte shares following the news.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.